S-LITE RCT (n=195) found combination of a moderate-to-vigorous–intensity exercise program and liraglutide treatment after diet-induced weight loss was more effective in improving healthy weight loss than exercise alone, at 1 year follow-up .
PIII study (NCT02918279; n=125) is published; it found liraglutide 3mg plus lifestyle therapy was superior to placebo plus lifestyle therapy, with regard to change from baseline in BMI standard-deviation score at week 56 (estimated difference, −0.22; 95% CI, −0.37 to −0.08; p=0.002) .
PIII study (NCT02918279) completes .
No results posted yet for PIII study (NCT02918279) .
PIII study (NCT02918279) has completed recruitment and is due to complete collecting primary outcome data (change in BMI) in Feb 2019 .
PIII trial to assess the efficacy of liraglutide SC injection for weight management in pubertal adolescent patients with obesity starts (NCT02918279). The 56-week, double-blind, randomised, parallel, placebo-controlled trial, followed by a 26-week period off study-drug, is designed to recruit 228 patients in the US, Belgium, Sweden, Mexico and Russia .